{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:21:20Z","timestamp":1791246080074,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Cancer Institute"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    We aim to evaluate relationships between the locations and success rates of United States oncology clinical trials by analyzing geographic features such as median income and proportion of practicing oncologists by ZIP code. A dataset of 15,658 trials with at least one site in the 50 states or the District of Columbia was collected by integrating trial outcomes curated in Trialtrove, locations from ClinicalTrials.gov, incomes from the U.S. Census, oncologist locations from the Center for Medicare Services and other sources. We found that ZIP codes in which trials are conducted are skewed away from lower median incomes (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20094.05e-08, Kolmogorov-Smirnov test). When ZIP codes were partitioned into lower, middle and upper terciles of median income, success rates by ZIP code were significantly lower in the low-income range relative to the middle- and higher-income ranges (lowest vs. highest\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.0001, OR 1.13 [1.10\u20131.16]). Trials conducted in more ZIP codes are significantly more likely to succeed than trials conducted in fewer ZIP codes. We identified candidate ZIP codes with sufficient patient populations and practicing oncologists to support clinical oncology trials but have never had a trial previously.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-39609-x","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T12:48:12Z","timestamp":1770814092000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Success rates of American clinical oncology trials by geographic factors"],"prefix":"10.1038","volume":"16","author":[{"given":"Sumeet","family":"Patiyal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro A.","family":"Sch\u00e4ffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"39609_CR1","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.arth.2021.11.006","volume":"37","author":"MS Broggi","year":"2022","unstructured":"Broggi, M. S. et al. Rural hospital designation is associated with increased complications and resource utilization after primary total hip arthroplasty: A matched case-control study. J. Arthroplasty. 37, 513\u2013517 (2022).","journal-title":"J. Arthroplasty"},{"key":"39609_CR2","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.1002\/cncr.34455","volume":"128","author":"NE Caston","year":"2022","unstructured":"Caston, N. E. et al. Associations between geography, decision-making style, and interest in cancer clinical trial participation. Cancer 128, 3977\u20133984 (2022).","journal-title":"Cancer"},{"key":"39609_CR3","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1007\/s00384-019-03436-6","volume":"34","author":"M Hamidi","year":"2019","unstructured":"Hamidi, M. et al. Does it matter where you get your surgery for colorectal cancer? Int. J. Colorectal Dis. 34, 2121\u20132127 (2019).","journal-title":"Int. J. Colorectal Dis."},{"key":"39609_CR4","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1200\/OP.20.00174","volume":"16","author":"LA Levit","year":"2020","unstructured":"Levit, L. A. et al. Closing the rural cancer care gap: three institutional approaches. JCO Oncol. Pract. 16, 422\u2013430 (2020).","journal-title":"JCO Oncol. Pract."},{"key":"39609_CR5","doi-asserted-by":"publisher","first-page":"e181235","DOI":"10.1001\/jamanetworkopen.2018.1235","volume":"1","author":"JM Unger","year":"2018","unstructured":"Unger, J. M. et al. Geographic distribution and survival outcomes for rural patients with cancer treated in clinical trials. JAMA Netw. Open. 1, e181235 (2018).","journal-title":"JAMA Netw. Open."},{"key":"39609_CR6","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1200\/OP.20.00352","volume":"16","author":"KR Yabroff","year":"2020","unstructured":"Yabroff, K. R., Han, X., Zhao, J., Nogueira, L. & Jemal, A. Rural cancer disparities in the united states: A multilevel framework to improve access to care and patient outcomes. JCO Oncol. Pract. 16, 409\u2013413 (2020).","journal-title":"JCO Oncol. Pract."},{"key":"39609_CR7","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1200\/JCO.20.02602","volume":"39","author":"JM Unger","year":"2021","unstructured":"Unger, J. M. et al. Persistent disparity: socioeconomic deprivation and cancer outcomes in patients treated in clinical trials. J. Clin. Oncol. 39, 1339\u20131348 (2021).","journal-title":"J. Clin. Oncol."},{"key":"39609_CR8","doi-asserted-by":"publisher","first-page":"e244008","DOI":"10.1001\/jamanetworkopen.2024.4008","volume":"7","author":"DL Hershman","year":"2024","unstructured":"Hershman, D. L. et al. Socioeconomic deprivation and health care use in patients enrolled in SWOG cancer clinical trials. JAMA Netw. Open. 7, e244008 (2024).","journal-title":"JAMA Netw. Open."},{"key":"39609_CR9","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s11605-021-05092-0","volume":"26","author":"VM Welten","year":"2022","unstructured":"Welten, V. M. et al. The effect of facility volume on survival following proctectomy for rectal cancer. J. Gastrointest. Surg. 26, 150\u2013160 (2022).","journal-title":"J. Gastrointest. Surg."},{"key":"39609_CR10","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1001\/jamainternmed.2014.6300","volume":"175","author":"MD Galsky","year":"2015","unstructured":"Galsky, M. D. et al. Geographic accessibility to clinical trials for advanced cancer in the united States. JAMA Intern. Med. 175, 293\u2013295 (2015).","journal-title":"JAMA Intern. Med."},{"key":"39609_CR11","first-page":"1","volume":"42","author":"CE Guerra","year":"2022","unstructured":"Guerra, C. E., Fleury, M. E., Byatt, L. P., Lian, T. & Pierce, L. Strategies to advance equity in cancer clinical trials. Am. Soc. Clin. Oncol. Educ. Book. 42, 1\u201311 (2022).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"key":"39609_CR12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40504-020-00104-4","volume":"16","author":"M Kermanimojarad","year":"2020","unstructured":"Kermanimojarad, M. What is the impact of patient recruitment on offshoring of clinical trials? Life Sci. Soc. Policy. 16, 10 (2020).","journal-title":"Life Sci. Soc. Policy"},{"key":"39609_CR13","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1038\/s41591-025-03926-x","volume":"31","author":"R Casolino","year":"2025","unstructured":"Casolino, R. et al. The WHO global landscape of cancer clinical trials. Nat. Med. 31, 2901\u20132912 (2025).","journal-title":"Nat. Med."},{"key":"39609_CR14","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1200\/OP.24.00261","volume":"21","author":"MK Kirkwood","year":"2025","unstructured":"Kirkwood, M. K. et al. State of geographic access to cancer treatment trials in the united states: are studies located where patients live? JCO Oncol. Pract. 21, 427\u2013437 (2025).","journal-title":"JCO Oncol. Pract."},{"key":"39609_CR15","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1001\/jamaoncol.2023.7314","volume":"10","author":"H Lee","year":"2024","unstructured":"Lee, H. et al. Analysis and optimization of equitable US cancer clinical trial center access by travel time. JAMA Oncol. 10, 652\u2013657 (2024).","journal-title":"JAMA Oncol."},{"key":"39609_CR16","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1111\/cts.13659","volume":"16","author":"P Moraga Alapont","year":"2023","unstructured":"Moraga Alapont, P. et al. Evaluation of factors associated with recruitment rates in early phase clinical trials based on the European clinical trials register data. Clin. Transl Sci. 16, 2654\u20132664 (2023).","journal-title":"Clin. Transl Sci."},{"key":"39609_CR17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1177\/17407745221149118","volume":"20","author":"MM Reid","year":"2023","unstructured":"Reid, M. M. et al. Demographic diversity of US-based participants in GSK-sponsored interventional clinical trials. Clin. Trials. 20, 133\u2013144 (2023).","journal-title":"Clin. Trials"},{"key":"39609_CR18","doi-asserted-by":"publisher","first-page":"e2410162","DOI":"10.1001\/jamanetworkopen.2024.10162","volume":"7","author":"RR Sekar","year":"2024","unstructured":"Sekar, R. R., Herrel, L. A. & Stensland, K. D. Social determinants of health and the availability of cancer clinical trials in the united States. JAMA Netw. Open. 7, e2410162 (2024).","journal-title":"JAMA Netw. Open."},{"key":"39609_CR19","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1200\/JOP.2010.000158","volume":"7","author":"S Virani","year":"2011","unstructured":"Virani, S., Burke, L., Remick, S. C. & Abraham, J. Barriers to recruitment of rural patients in cancer clinical trials. J. Oncol. Pract. 7, 172\u2013177 (2011).","journal-title":"J. Oncol. Pract."},{"key":"39609_CR20","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1002\/cpt.1627","volume":"107","author":"JA DiMasi","year":"2020","unstructured":"DiMasi, J. A. et al. Development times and approval success rates for drugs to treat infectious diseases. Clin. Pharmacol. Ther. 107, 324\u2013332 (2020).","journal-title":"Clin. Pharmacol. Ther."},{"key":"39609_CR21","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.drudis.2019.12.014","volume":"25","author":"F Feijoo","year":"2020","unstructured":"Feijoo, F., Palopoli, M., Bernstein, J., Siddiqui, S. & Albright, T. E. Key indicators of phase transition for clinical trials through machine learning. Drug Discov Today. 25, 414\u2013421 (2020).","journal-title":"Drug Discov Today"},{"key":"39609_CR22","doi-asserted-by":"crossref","unstructured":"Hegge, S. et al. Predicting success of Phase III trials in oncology: Meta-analysis of phase II and phase III trials initiated between 2003 and 2012 to generate a decision analytical model predicting success of future phase III trials. medRxiv preprint 2020.12.15.20248240 (2020).","DOI":"10.1101\/2020.12.15.20248240"},{"key":"39609_CR23","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s43441-023-00509-1","volume":"57","author":"E Kim","year":"2023","unstructured":"Kim, E., Yang, J., Park, S. & Shin, K. Factors affecting success of new drug clinical trials. Ther. Innov. Regul. Sci. 57, 737\u2013750 (2023).","journal-title":"Ther. Innov. Regul. Sci."},{"key":"39609_CR24","doi-asserted-by":"publisher","first-page":"100312","DOI":"10.1016\/j.patter.2021.100312","volume":"2","author":"KW Siah","year":"2021","unstructured":"Siah, K. W. et al. Predicting drug approvals: the Novartis data science and artificial intelligence challenge. Patterns (N Y). 2, 100312 (2021).","journal-title":"Patterns (N Y)"},{"key":"39609_CR25","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","volume":"20","author":"CH Wong","year":"2019","unstructured":"Wong, C. H., Siah, K. W. & Lo, A. W. Estimation of clinical trial success rates and related parameters. Biostatistics 20, 273\u2013286 (2019).","journal-title":"Biostatistics"},{"key":"39609_CR26","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1038\/s41598-021-82840-x","volume":"11","author":"ME Elkin","year":"2021","unstructured":"Elkin, M. E. & Zhu, X. Predictive modeling of clinical trial terminations using feature engineering and embedding learning. Sci. Rep. 11, 3446 (2021).","journal-title":"Sci. Rep."},{"key":"39609_CR27","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.ipm.2018.11.009","volume":"56","author":"L Follett","year":"2019","unstructured":"Follett, L., Geletta, S. & Laugerman, M. Quantifying risk associated with clinical trial termination: A text mining approach. Inf. Proc. Man. 56, 516\u2013525 (2019).","journal-title":"Inf. Proc. Man."},{"key":"39609_CR28","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s12911-019-0973-y","volume":"19","author":"S Geletta","year":"2019","unstructured":"Geletta, S., Follett, L. & Laugerman, M. Latent dirichlet allocation in predicting clinical trial terminations. BMC Med. Inf. Decis. Mak. 19, 242 (2019).","journal-title":"BMC Med. Inf. Decis. Mak."},{"key":"39609_CR29","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41598-023-27416-7","volume":"13","author":"E Kavalci","year":"2023","unstructured":"Kavalci, E. & Hartshorn, A. Improving clinical trial design using interpretable machine learning based prediction of early trial termination. Sci. Rep. 13, 121 (2023).","journal-title":"Sci. Rep."},{"key":"39609_CR30","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/cbdd.14092","volume":"100","author":"V Murali","year":"2022","unstructured":"Murali, V. et al. Predicting clinical trial outcomes using drug bioactivities through graph database integration and machine learning. Chem. Biol. Drug Des. 100, 169\u2013184 (2022).","journal-title":"Chem. Biol. Drug Des."},{"key":"39609_CR31","doi-asserted-by":"publisher","first-page":"5517","DOI":"10.1002\/cam4.5385","volume":"12","author":"E Zhang","year":"2023","unstructured":"Zhang, E. & DuBois, S. G. Early termination of oncology clinical trials in the united States. Cancer Med. 12, 5517\u20135525 (2023).","journal-title":"Cancer Med."},{"key":"39609_CR32","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1002\/cpt.3008","volume":"114","author":"A Aliper","year":"2023","unstructured":"Aliper, A. et al. Prediction of clinical trials outcomes based on target choice and clinical trial design with multi-modal artificial intelligence. Clin. Pharmacol. Ther. 114, 972\u2013980 (2023).","journal-title":"Clin. Pharmacol. Ther."},{"key":"39609_CR33","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1186\/s13063-019-3957-4","volume":"20","author":"M Briel","year":"2019","unstructured":"Briel, M., Speich, B., von Elm, E. & Gloy, V. Comparison of randomized controlled trials discontinued or revised for poor recruitment and completed trials with the same research question: a matched qualitative study. Trials 20, 800 (2019).","journal-title":"Trials"},{"key":"39609_CR34","doi-asserted-by":"publisher","first-page":"100445","DOI":"10.1016\/j.patter.2022.100445","volume":"3","author":"T Fu","year":"2022","unstructured":"Fu, T., Huang, K., Xiao, C., Glass, L. M. & Sun, J. HINT: hierarchical interaction network for clinical-trial-outcome predictions. Patterns 3, 100445 (2022).","journal-title":"Patterns"},{"key":"39609_CR35","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.chembiol.2016.07.023","volume":"23","author":"KM Gayvert","year":"2016","unstructured":"Gayvert, K. M., Madhukar, N. S. & Elemento, O. A data-driven approach to predicting successes and failures of clinical trials. Cell. Chem. Biol. 23, 1294\u20131301 (2016).","journal-title":"Cell. Chem. Biol."},{"key":"39609_CR36","doi-asserted-by":"publisher","first-page":"e38859","DOI":"10.2196\/38859","volume":"24","author":"S Wang","year":"2022","unstructured":"Wang, S., \u0160uster, S., Baldwin, T. & Verspoor, K. Predicting publication of clinical trials using structured and unstructured data: model development and validation study. J. Med. Internet Res. 24, e38859 (2022).","journal-title":"J. Med. Internet Res."},{"key":"39609_CR37","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1208\/s12248-022-00703-3","volume":"24","author":"K Wu","year":"2022","unstructured":"Wu, K. et al. Machine learning prediction of clinical trial operational efficiency. AAPS J. 24, 57 (2022).","journal-title":"AAPS J."},{"key":"39609_CR38","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2307\/2531595","volume":"44","author":"ER DeLong","year":"1988","unstructured":"DeLong, E. R., DeLong, D. M. & Clarke-Pearson, D. L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44, 837\u2013845 (1988).","journal-title":"Biometrics"},{"key":"39609_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejim.2024.03.006","volume":"123","author":"R Dal-R\u00e9","year":"2024","unstructured":"Dal-R\u00e9, R. Is full transparency in clinical trials an achievable goal? Eur. J. Intern. Med. 123, 1\u20133 (2024).","journal-title":"Eur. J. Intern. Med."},{"key":"39609_CR40","doi-asserted-by":"publisher","first-page":"e049228","DOI":"10.1136\/bmjopen-2021-049228","volume":"11","author":"C Ohmann","year":"2021","unstructured":"Ohmann, C., Moher, D., Siebert, M., Motschall, E. & Naudet, F. Status, use and impact of sharing individual participant data from clinical trials: a scoping review. BMJ Open. 11, e049228 (2021).","journal-title":"BMJ Open."},{"key":"39609_CR41","doi-asserted-by":"publisher","first-page":"k400","DOI":"10.1136\/bmj.k400","volume":"360","author":"F Naudet","year":"2018","unstructured":"Naudet, F. et al. Data sharing and reanalysis of randomized controlled trials in leading biomedical journals with a full data sharing policy: survey of studies published in The BMJ and PLOS medicine. BMJ 360, k400 (2018).","journal-title":"BMJ"},{"key":"39609_CR42","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1177\/2168479018782885","volume":"53","author":"S Stergiopoulos","year":"2019","unstructured":"Stergiopoulos, S., Getz, K. A. & Blazynski, C. Evaluating the completeness of ClinicalTrials.gov. Ther. Innov. Regul. Sci. 53, 307\u2013317 (2019).","journal-title":"Ther. Innov. Regul. Sci."},{"key":"39609_CR43","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1001\/jamainternmed.2013.627","volume":"173","author":"BR Hirsch","year":"2013","unstructured":"Hirsch, B. R. et al. Characteristics of oncology clinical trials: insights from a systematic analysis of ClinicalTrials.gov. JAMA Intern. Med. 173, 972\u2013979 (2013).","journal-title":"JAMA Intern. Med."},{"key":"39609_CR44","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaoncol.2024.1690","volume":"10","author":"WT Swenson","year":"2024","unstructured":"Swenson, W. T., Swenson, A., Westergard, E. & Schroeder, Z. Geographic distribution of clinical trials for advanced-stage cancer. JAMA Oncol. 10, 1132\u20131133 (2024).","journal-title":"JAMA Oncol."},{"key":"39609_CR45","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1038\/s41467-024-46945-x","volume":"15","author":"AV Kammula","year":"2024","unstructured":"Kammula, A. V., Schaffer, A. A., Rajagopal, P. S., Kurzrock, R. & Ruppin, E. Outcome differences by sex in oncology clinical trials. Nat. Commun. 15, 2608 (2024).","journal-title":"Nat. Commun."},{"key":"39609_CR46","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13045-022-01227-1","volume":"15","author":"D Wu","year":"2022","unstructured":"Wu, D. et al. The global landscape of neoadjuvant and adjuvant anti-PD-1\/PD-L1 clinical trials. J. Hematol. Oncol. 15, 16 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"39609_CR47","doi-asserted-by":"crossref","unstructured":"Aggarwal, C. C. Outlier Analysis (Springer, 2017).","DOI":"10.1007\/978-3-319-47578-3"},{"key":"39609_CR48","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1056\/NEJMp1802313","volume":"378","author":"AJH Kind","year":"2018","unstructured":"Kind, A. J. H. & Buckingham, W. R. Making neighborhood-disadvantage metrics accessible - The neighborhood atlas. N Engl. J. Med. 378, 2456\u20132458 (2018).","journal-title":"N Engl. J. Med."},{"key":"39609_CR49","first-page":"277","volume":"20","author":"R Wilson","year":"2018","unstructured":"Wilson, R. & Din, A. Understanding and enhancing the U.S department of housing and urban development\u2019s ZIP code crosswalk files. Cityscape 20, 277\u2013294 (2018).","journal-title":"Cityscape"},{"key":"39609_CR50","first-page":"293","volume":"22","author":"A Din","year":"2020","unstructured":"Din, A. & Wilson, R. Crosswalking ZIP codes to censu geographies: geoprocessing the U.S. Department of housing & urban development\u2019s ZIP code crosswalk files. Cityscape 22, 293\u2013314 (2020).","journal-title":"Cityscape"},{"key":"39609_CR51","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1200\/JCO.2002.08.056","volume":"20","author":"WB Sateren","year":"2002","unstructured":"Sateren, W. B. et al. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J. Clin. Oncol. 20, 2109\u20132117 (2002).","journal-title":"J. Clin. Oncol."},{"key":"39609_CR52","first-page":"2825","volume":"12","author":"F Pedregosa","year":"2011","unstructured":"Pedregosa, F., Varoquaux, G., Gramfort, A., Michel, V. & Thirion, B. Scikit-learn:Machine learning in python. J. Mach. Learn. Res. 12, 2825\u20132830 (2011).","journal-title":"J. Mach. Learn. Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39609-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39609-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39609-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T14:02:26Z","timestamp":1772805746000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39609-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["39609"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-39609-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"2 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8353"}}